N-(m-PEG4)-N'-(Acid-PEG3)-benzothiazole Cy5
Code | Size | Price |
---|
TAR-T18421-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T18421-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
N-(m-PEG4)-N'-(Acid-PEG3)-benzothiazole Cy5 is a polyethylene glycol-based linker termed PEG-PROTAC, suitable for the development of PROTACs through chemical synthesis[1].
CAS:
2107273-80-1
Molecular Weight:
765.38
Purity:
0.98
SMILES:
[Cl-].O=C(O)CCOCCOCCOCCN1C(SC=2C=CC=CC21)=CC=CC=CC=3SC=4C=CC=CC4[N+]3CCOCCOCCOCCOC
References
An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.